CD274 and neoplasm: The biomarker-guided therapies have recently been approved, including poly-ADP ribose polymerase inhibitors for patients with germline BRCA mutations and atezolizumab in conjunction with nab-paclitaxel for patients expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells.